EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases

Jessica R Crawshaw, Eamonn A Gaffney, Michael Gertz, Philip K Maini, Antonello Caruso

Investigative Ophthalmology & Visual Science · 2025

DOI: 10.1167/iovs.66.6.20 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Jessica R Crawshaw and 4 co-authors. Institution: Wolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, United Kingdom. Major MEDLINE topics: Ranibizumab, Angiogenesis Inhibitors, Aqueous Humor, Models, Biological. Cited 5 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

Improving our understanding of the ocular pharmacokinetics and pharmacodynamics of anti-vascular endothelial growth factor (VEGF) therapies, such as ranibizumab, is essential to enhance treatment strategies for a range of retinal diseases, and will help inform the development of novel anti-VEGF drug candidates.

Methods

In this study, we examine a two-compartment pharmacokinetic/pharmacodynamic model of an intravitreal ranibizumab injection to understand its impact on ocular VEGF suppression. We use Bayesian inference to infer the model parameters from aqueous humor data extracted from healthy cynomolgus macaques. We leverage this approach to explore various sources of uncertainty in the data, offering practical recommendations for minimizing avoidable uncertainty.

Results

The model provides a robust description of ranibizumab pharmacokinetics and pharmacodynamics, identifying the recovery region of the aqueous humor VEGF concentration-time profile as critical for the precise estimation of parameters. Our results advocate focusing on this region in future studies for optimal data collection. We consider standard data correction techniques to reduce the data uncertainty introduced by the lower limit of quantification, identifying the most preferable technique for this model and data. Using a Bayesian approach we obtain an inferred mean posterior distribution of 1459 ± 98 pM for the ranibizumab dissociation constant, a pharmacodynamic parameter with notable variability across the literature.

Conclusions

This study extends our understanding of the ocular pharmacokinetics and pharmacodynamics of ranibizumab and provides theoretical insights for enhanced data collection schemes to be considered for clinical trials and in the development of novel anti-VEGF therapies.

Subjects

MeSH terms (MEDLINE)

RanibizumabAngiogenesis InhibitorsAqueous HumorModels, BiologicalAnimalsIntravitreal InjectionsMacaca fascicularisVascular Endothelial Growth Factor ABayes Theorem

Substances

RanibizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Authors and institutions

  • Wolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, United Kingdom.
  • Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland.

Cite

APA

Crawshaw, J. R., Gaffney, E. A., Gertz, M., Maini, P. K., & Caruso, A. (2025). Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.6.20

Vancouver

Crawshaw JR, Gaffney EA, Gertz M, Maini PK, Caruso A. Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.6.20

BibTeX
@article{Crawshaw2025,
  author = {Crawshaw, Jessica R and Gaffney, Eamonn A and Gertz, Michael and Maini, Philip K and Caruso, Antonello},
  title = {Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2025},
  doi = {10.1167/iovs.66.6.20}
}
Start for free →